Moderately impaired renal function is a common reason for not initiating treatment with Mineralocorticoid receptor antagonists (MRA) in clinical practice in patients with heart failure with reduced ejection fraction (HFrEF) [1, 2], due to the fear of worsening renal function (WRF) and hyperkalemia. This evidence concerns the gene NR3C2 and heart failure.